Med Life SA · BVB:M
Med Life SA — FY2018 Earnings Presentation
15 slides from Med Life SA's earnings presentation, 2019
Slide 1: Conference Call Presentation for 2018 Preliminary Results
Conference Call Presentation for 2018 Preliminary Results
Slide 2: Legal Disclaimer
LEGAL DISCLAIMER This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of Med Life SA’s securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy Med Life SA’s securities. Neither this presentat
Slide 3: Topics of Discussion
TOPICS OF DISCUSSION PAGE I. Q4 2018 AT A GLANCE & SUBSEQUENT EVENTS 4 II. KEY CHANGES 2018 vs 2017 6 III. MISSION STATEMENT & EVOLUTION 8 IV. MEDLIFE 2018 FINANCIAL SNAPSHOT 10 V. KEY OPERATIONAL METRICS FOR 2018 13 VI. Q&A SESSION 14 Page 3
Slide 4: Q4 2018 at a Glance
Q4 2018 AT A GLANCE ORGANIC GROWTH • Bacau Clinic – under Sfanta Maria, the second brand of MedLife • Oradea Hyperclinic EXPANSION PLANS • Grivita Hospital (additional 57 beds and 2 surgery rooms) – completed by December 2018 CREDIT FACILITIES CONTRACTED BY THE GROUP • MedLife signed a new syndicate
Slide 5: & Subsequent Events
& SUBSEQUENT EVENTS ACQUISITIONS • MedLife crossed the country`s boarders and announced the first international transaction through the acquisition of 51% stake in Rózsakert Medical Center (RMC) Group of companies, one of top 10 medical services providers in Hungary. In 2017 RMC Group registered a t
Slide 6: Key Changes 2018 vs 2017
KEY CHANGES 2018 vs 2017 Sales increased by : + 29% Pro-forma 2018 vs. IFRS 2017 SALES + 27.5% IFRS 2018 vs. IFRS 2017 vs. market increase by approx. 10%* + 12.9% like2like Absolute value of EBITDA increased by 32.7% Pro-forma 2018 vs. IFRS 2017 improved EBITDA margin : 12.9% Pro-Forma IFRS 2018 vs.
Slide 7: Key Changes 2018 vs 2017 (Cont.)
KEY CHANGES 2018 vs 2017 (Cont.) IFRS EBITDA is consistent with CF before WC and other monetary changes, as IFRS EBITDA was 95.4m RON, 9.3% while CF before WC and other monetary changes was 92m RON. Split of Pro-forma EBITDA between Owners of the Group / NCI for 2018: EBITDA - 90.7% to Group Owners
Slide 8: Mission Statement & Evolution
MISSION STATEMENT & EVOLUTION 2016 IFRS 2017 IFRS 2018 Pro-forma IFRS Consistent track record of strong 502.9 mRON 623.2 mRON, increased by 24% 804 mRON, increased by 29% growth of Sales MedLife units as at 31 December MedLife units as at 31 December MedLife units as at 31 December through acquisiti
Slide 9: Mission Statement & Evolution (Cont.)
MISSION STATEMENT & EVOLUTION (Cont.) 2016 IFRS 2017 IFRS 2018 Pro-forma IFRS EBITDA evolution in 54.6 mRON 77.9 mRON, increased by 43% 103.4 mRON, increased by 33% absolute figures Sustainable and improved EBITDA 10.9% EBITDA margin 12.5% EBITDA margin 12.9% EBITDA margin margin Market Capitalizati
Slide 10: MedLife Group 2018 Financial Snapshot – preliminary results
MEDLIFE GROUP 2018 FINANCIAL SNAPSHOT – preliminary results Consolidated Statement of Financial Position Consolidated Statement of Profit and Loss Page 10
Slide 11: MedLife Group 2018 Financial Snapshot – Cash Flow
MEDLIFE GROUP 2018 FINANCIAL SNAPSHOT – preliminary results Consolidated Statement of Cash Flow IFRS EBITDA is consistent with operating CF before WC and other monetary changes Page 11
Slide 12: MedLife Group 2018 Financial Snapshot – OPEX Evolution
MEDLIFE GROUP 2018 FINANCIAL SNAPSHOT – preliminary results OPEX EVOLUTION Note: The Group recorded a 0.9 p.p. increase of operating expenses as % of sales in 2018 as compared to 2017. A. 0.9 p.p. decrease of “Rent" as % of Sales; and B. 1.2 p.p. increase of “Third parties and salaries expenses” as
Slide 13: Key Operational Metrics for 2018 – preliminary results
KEY OPERATIONAL METRICS FOR 2018 – preliminary results Page 13
Slide 14: Q&A Session
© Med Life IV. Q&A SESSION as Ras Page 14
Slide 15: Thank You!
THANK YOU! © MedLife